Calixis

Calixis is a French biotechnology company focused on the discovery and development of novel small molecule therapeutics targeting the P2X7 receptor. The company addresses significant unmet medical needs in the fields of inflammation, autoimmunity, and neurodegeneration by modulating the P2X7-mediated inflammasome pathway. By inhibiting this receptor, Calixis aims to prevent the release of key pro-inflammatory cytokines such as IL-1β and IL-18. The company's research is rooted in deep expertise in purinergic signaling and is supported by collaborations with leading French academic institutions. Currently, Calixis is advancing its lead candidates through pre-clinical development to establish a pipeline of potent and selective P2X7 antagonists.